Page 6,407«..1020..6,4066,4076,4086,409..6,4206,430..»

Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

Posted: February 21, 2012 at 8:16 pm

CAMBRIDGE, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diabetes and other diseases characterized by organ-specific cell damage, today presented preliminary data highlighting the potential of the Company's unique cell-based therapy for treating diabetes at the 7th Annual New York Stem Cell Summit. Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, provided an overview of the Company's Pathfinder Cell ("PC") technology, and presented preclinical evidence demonstrating how treatment with PCs was able to reverse the symptoms of diabetes in two different mouse models. Pathfinder Cells are a newly identified non-stem cell mammalian cell type that has the ability to stimulate regeneration of damaged tissue without being incorporated into the new tissue. In today's presentation, Dr. Franklin showed how recent experiments performed using a non-obese diabetic (NOD) mouse strain were supportive of earlier data that demonstrated complete reversal of diabetes in mice. The earlier results, which used a drug-induced diabetic mouse model, were published in Rejuvenation Research1. Though preliminary, the recent results are encouraging because the NOD mouse model is widely used and highly regarded as being predictive of human … Continue reading

Comments Off on Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

Celling Biosciences Sponsors 7th Annual Stem Cell Summit

Posted: at 8:16 pm

AUSTIN, Texas, Feb. 21, 2012 /PRNewswire/ -- Celling Biosciences announces a sponsorship of the 7th Annual Stem Cell Summit being held on February 21st at Bridgewaters New York in New York City. The Stem Cell Summit is consistently the premiere venue for the world's leaders in regenerative medicine to network and promote next generation technologies and cell therapies. The meeting will feature more than 30 thought leaders in stem cell therapy including Dr. Kenneth Pettine of the Orthopedic Stem Cell Institute in Loveland, Colorado.  Dr. Pettine has teamed up with Celling Biosciences' SpineSmith Division to present "Adult Stem Cell Therapy for Orthopedic and Spine Conditions Resulting from Injury or Aging."  Dr. Pettine has become an innovator in the regenerative cell therapy market and believes "regenerative therapies will become the next standard of care in treating many orthopedic conditions."  Following the Stem Cell Summit, Dr. Pettine will be presenting a discussion on regenerative therapies to the trainers and medical staff attending this year's NFL combine.  The NFL has recently gained attention from Peyton Manning going oversees to receive a cell therapy treatment for his cervical spine condition.  Dr. Pettine envisions a day when these professional athletes stop going to foreign countries to … Continue reading

Comments Off on Celling Biosciences Sponsors 7th Annual Stem Cell Summit

VistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor

Posted: at 8:16 pm

ATLANTA, GA--(Marketwire -02/21/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB - News) (OTCQB: VSTA.OB - News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has retained MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Through a network of investor-oriented online websites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital and improve shareholder value. "VistaGen's work with human stem cell technology is groundbreaking," said Sherri Snyder, Director of Marketing at MissionIR. "The company's versatile platform, Human Clinical Trials in a Test Tube™, provides clinically relevant predictions of potential heart toxicity of new drug candidates long before they are ever tested on humans. Guided by a management team with decades of experience, VistaGen's stem cell technology can potentially save billions of dollars in the healthcare industry while recapturing prior R&D investment in once-promising new drug candidates." "We are pleased to bring MissionIR on board as our external investor relations partner," said Shawn Singh, VistaGen's Chief Executive Officer. "The crucial work our company is doing can fundamentally change the way medicine is developed. Paired with MissionIR's global … Continue reading

Comments Off on VistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor

IBM and IBN Treating MRSA With Nanotechnology and Nanomedicine in February's Edition of Healthcare Global

Posted: at 8:16 pm

SOURCE: Healthcare Global NORWICH, UNITED KINGDOM--(Marketwire - Feb 21, 2012) - In April 2011 researchers from IBM and the Institute of Bioengineering and Nanotechnology (IBN) announced that they had stumbled on "a nanomedicine breakthrough." They discovered a new type of polymer which was able to detect and destroy bacteria that is resistant to antibiotics and infectious diseases such as MRSA. It is now hoped the discovery will have the potential to revolutionise treatments for MRSA and other superbugs which are becoming increasingly common in hospitals and healthcare environments across the world. If commercially manufactured, these biodegradable nanostructures could be injected directly into the body or applied topically to the skin, treating skin infections through consumer products like deodorant, soap and hand sanitizer, as well as being used to help heal wounds, tuberculosis and lung infections. To get a more up-to-date picture of how the discovery and development of this innovative new technique is progressing, Healthcare Global caught up with Dr James Hedrick, an IBM research scientist, in its March issue. To read this article in full, visit http://www.healthcareglobal.com or read the February issue Healthcare Global digital magazine. About Healthcare Global Healthcare Global is a pioneering digital media site for Healthcare … Continue reading

Comments Off on IBM and IBN Treating MRSA With Nanotechnology and Nanomedicine in February's Edition of Healthcare Global

Renato Dulbecco dies at 97; 1975 Nobel Prize winner in medicine

Posted: at 7:02 pm

Dr. Renato Dulbecco, an Italian American virologist who shared the 1975 Nobel Prize in physiology or medicine for demonstrating how certain types of viruses invade mammalian cells to cause cancer, died of natural causes Sunday at his home in La Jolla. He was 97. Dulbecco developed a method for measuring the quantity of virus in animal cells in tissue culture, a finding that greatly facilitated the study of such viruses and paved the way for the development of the Sabin polio vaccine. He was a faculty member at Caltech from 1949 to 1963 before moving to the Salk Institute for Biological Studies in La Jolla. He later served as president of the institute. Dulbecco was also one of the first proponents of the human genome project, which many researchers initially thought would be both excessively expensive and relatively useless but which has since proved invaluable in biological research. "Renato was one of the most brilliant scientific minds of our generation," current Salk Institute President William R. Brody said in a statement. "His contributions have truly made this a better world for all of us." It has been known since the early 1900s that certain viruses can cause tumors in animals. … Continue reading

Posted in Cell Medicine | Comments Off on Renato Dulbecco dies at 97; 1975 Nobel Prize winner in medicine

Italian Nobel medicine winner Dulbecco dies at 97

Posted: at 7:02 pm

ROME (AP) — Renato Dulbecco, who shared the 1975 Nobel Prize in medicine for his seminal research on the interaction between tumors and cells, has died in California. He was 97. Dulbecco, an early proponent of sequencing genomes that led to the Human Genome Project, died in La Jolla, California overnight, Italy's National Research Council — where Dulbecco worked on the genome project in the 1990s — said Monday. Dulbecco was a founding fellow of the La Jolla-based Salk Institute for Biological Studies, where he was an emeritus president and distinguished professor. He moved from Italy to California early in his career, working first at Caltech in 1949, then at Salk in 1962, and then onwards to England, where he worked at the Imperial Cancer Research Fund Laboratories in London from 1972-1977. Dulbecco — who would have been 98 on Wednesday — shared the Nobel prize in medicine in 1975 along with David Baltimore and Howard Martin Temin "for their discoveries concerning the interaction between tumor viruses and the genetic material of the cell" according to the Nobel committee. His prize-winning research gave the first clue to the genetic nature of cancer, showing how a virus could insert its own … Continue reading

Posted in Cell Medicine | Comments Off on Italian Nobel medicine winner Dulbecco dies at 97

Biocept to Present at the Molecular Medicine Tri-Conference on Circulating Tumor Cell (CTC) Technologies

Posted: at 7:02 pm

SAN DIEGO--(BUSINESS WIRE)-- Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that two of its senior scientists, Farideh Bischoff, Ph.D., Vice President of Translational Research, and Lyle Arnold, Ph.D., Senior Vice President, R&D and Chief Scientific Officer, will be making presentations at the 19th Annual Molecular Medicine Tri-Con being held in San Francisco February 19-23. Dr. Arnold spoke during the “Blood-Based Cancer Diagnostics” session on Monday, February 20th. His talk, entitled “The Capture, Identification and Interrogation of Circulating Tumor Cells,” touched on a proprietary, highly sensitive mutation detection technology developed at Biocept called “SelectorTM.” Dr. Bischoff will speak during the “Clinical Use of Circulating Tumor Cells” session on Wednesday, February 22nd. Her talk, entitled “Capture and Detection of CK+ and CK- CTCs for Subsequent Molecular Analysis Using the OncoCEETM Platform,” will cover in part a continuing clinical study in breast cancer with collaborators at the MD Anderson Cancer Center. Biocept’s first test, OncoCEE-BRTM for breast cancer, is available through its commercialization partner Clarient, Inc., a GE Healthcare Company. The test includes CTC enumeration and determination of HER2 status by fluorescence in situ hybridization (FISH) from … Continue reading

Posted in Cell Medicine | Comments Off on Biocept to Present at the Molecular Medicine Tri-Conference on Circulating Tumor Cell (CTC) Technologies

Cell energy sensor mechanism discovered: Studies linked to better understanding of cancer drugs

Posted: at 7:02 pm

In a report in the Feb. 9 edition of Nature, the researchers showed that a chemical modification on the thermostat protein changes how it's controlled. Without the modification, cells use stored energy, and with it, they default to stockpiling resources. When cells don't properly allocate their energy supply, they can die off or become cancerous. The Johns Hopkins team focused especially on enzymes that add or remove so-called acetyl groups from protein molecules. "Understanding how cells are affected by adding acetyl groups to proteins, particularly those involved in energy use, is important because there is increasing use of drugs that block acetyl-removing enzymes for treatment of cancer and neurodegenerative diseases," says Jef Boeke, Ph.D., professor of molecular biology, genetics and oncology, and director of the High Throughput Biology Center at the Johns Hopkins University School of Medicine. "Blocking acetyl-removing enzymes turns on anticancer genes that help fight cancer; however, it is not known what other genes and cellular processes may also be affected by these treatments." To determine which enzymes remove acetyl chemical groups from which proteins, the researchers engineered human cells with reduced levels of each of 12 enzymes known to remove acetyl chemical groups. In each of these … Continue reading

Posted in Cell Medicine | Comments Off on Cell energy sensor mechanism discovered: Studies linked to better understanding of cancer drugs

Cell energy sensor mechanism discovered

Posted: at 7:02 pm

Public release date: 21-Feb-2012 [ | E-mail | Share ] Contact: Vanessa McMains vmcmain1@jhmi.edu 410-502-9410 Johns Hopkins Medical Institutions Johns Hopkins and National Taiwan University researchers have discovered more details about how an energy sensing "thermostat" protein determines whether cells will store or use their energy reserves. In a report in the Feb. 9 edition of Nature, the researchers showed that a chemical modification on the thermostat protein changes how it's controlled. Without the modification, cells use stored energy, and with it, they default to stockpiling resources. When cells don't properly allocate their energy supply, they can die off or become cancerous. The Johns Hopkins team focused especially on enzymes that add or remove so-called acetyl groups from protein molecules. "Understanding how cells are affected by adding acetyl groups to proteins, particularly those involved in energy use, is important because there is increasing use of drugs that block acetyl-removing enzymes for treatment of cancer and neurodegenerative diseases," says Jef Boeke, Ph.D., professor of molecular biology, genetics and oncology, and director of the High Throughput Biology Center at the Johns Hopkins University School of Medicine. "Blocking acetyl-removing enzymes turns on anticancer genes that help fight cancer; however, it is not known … Continue reading

Posted in Cell Medicine | Comments Off on Cell energy sensor mechanism discovered

Research and Markets: Evolutionary Biology: Cell-Cell Communication, and Complex Disease – An Integrative View of the …

Posted: at 7:02 pm

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b93d9c/evolutionary_biolo) has announced the addition of John Wiley and Sons Ltd's new book "Evolutionary Biology: Cell-Cell Communication, and Complex Disease" to their offering. Evolutionary Biology: Cell-Cell Communication, and Complex Disease - An Integrative View of the Evolution of Genetics and the Natural World Even in this advanced age of genomics, the evolutionary process of unicellular and multicellular organisms is continually in debate. Evolutionary Biology, Cell-Cell Communication, and Complex Disease challenges current wisdom by using physiology to present an integrative view of the nature, origins, and evolution of fundamental biological systems. Providing a deeper understanding of the way genes relate to the traits of living organisms, this book offers useful information applying evolutionary biology, functional genomics, and cell communication studies to complex disease. Examining the 4.5 billion-year evolution process from environment adaptations to cell-cell communication to communication of genetic information for reproduction, Evolutionary Biology hones in on the "why and how" of evolution by uniquely focusing on the cell as the smallest unit of biologic structure and function. Based on empirically derived data rather than association studies, Evolutionary Biology covers: A model for forming testable hypotheses in complex disease studies The integrating role played by the … Continue reading

Posted in Cell Medicine | Comments Off on Research and Markets: Evolutionary Biology: Cell-Cell Communication, and Complex Disease – An Integrative View of the …

Page 6,407«..1020..6,4066,4076,4086,409..6,4206,430..»